Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

View all content

HBW Insight

Vitamin D, Omega-3 No Help For Diabetics Against CKD, VITAL Data Show

By Eileen Francis 13 Nov 2019

In latest study casting doubt on the nutrients' effect on chronic illness, researchers find vitamin D and fish oil ineffective in staving off type 2 diabetics' kidney failure. Editorial also published in JAMA says further research is needed to analyze the nutrients’ possible benefits to diabetics with chronic kidney disease.

Topic Clinical trials

View article
HBW Insight

Novartis Wins Second Landmark German Case, This Time For Probiotics

By David Ridley 13 Nov 2019

Following a landmark win against the German government for the Rx-to-OTC switch of desloratadine last month, Novartis has again secured a victory in the German Higher Court system, this time to continue marketing its Biosan probiotics range in the country.

Topic Company analysis Policy and regulation

View article
Generics Bulletin

Aurobindo Is Company Of The Year At GGB Awards

By David Wallace 13 Nov 2019

Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.

Topic Biosimilars

View article
Generics Bulletin

Lupin Offloads Kyowa For $525m But Not Exiting Japan

By Vibha Ravi 13 Nov 2019

Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

Topic Deal trends Strategy

View analysis
Scrip

Five Trials To Look Out For At The AHA Meeting

By Alex Shimmings 13 Nov 2019

Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.

Topic Clinical trials Company analysis Research

View article
Scrip

Embracing China 2.0: AZ, Merck KGaA Set Up Funds, J&J Steps Up Digital Push

By Brian Yang 13 Nov 2019

AstraZeneca has pledged $1bn to a healthcare fund to support local innovation in China, joining big pharma peers J&J and Merck KGaA in fresh moves to embrace this market, where a new wave of digital technology transformation and fast-shifting trends now favor novel new therapies and the rise of local health start-ups.

Topic Digital Health

View article
HBW Insight

Homeopathic Market Doesn't 'Disappear' - FDA Forced To Act

By Malcolm Spicer 08 Nov 2019

"This was an area that the agency thought was just going to disappear on its own," says Freddie Ann Hoffman, who chaired FDA homeopathic working group that helped develop CPG adopted in 1988 to allow sales of homeopathics to continue without pre-market approval.

Topic FDA Policy and regulation

View article
HBW Insight

Zantac Recall And EU Regulatory Issues Hurt Sanofi In Q3

By Tom Gallen 08 Nov 2019

Recalling Zantac in North America over contamination concerns and tightening regulatory requirements in Europe combined to impede growth at Sanofi Consumer Healthcare in Q3. New CEO Paul Hudson says he is still taking time to get to know the business before making any strategic moves.

Topic Policy and regulation

View article
Generics Bulletin

Teva Debuts US Rituximab At A 10% Discount

By David Wallace 08 Nov 2019

Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.

Topic Biosimilars Strategy

View article
Scrip

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalise $3bn Deal

By Ian Haydock 06 Nov 2019

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

Topic Business strategies Deal trends

View article
Scrip

Amarin's Vascepa Momentum Builds Ahead Of Next Week's FDA AdComm

By Jessica Merrill 06 Nov 2019

Sales of the triglyceride-lowering medicine soared to $112.4m in the third quarter even before a label expansion that depends on the outcome of a vital US FDA advisory committee meeting on 14 November.

Topic Business strategies Company analysis

View article
Generics Bulletin

The US Biosimilars Perspectives

04 Nov 2019

As the push to promote the uptake of biosimilars in the US gains more momentum, new opportunities and challenges arise. Keep in tune with important developments in this impactful area using market coverage from Generics Bulletin.

Topic Biosimilars

Single report
Generics Bulletin

Pfizer Lines Up Trio Of US Biosimilar Launches

By Aidan Fry 01 Nov 2019

By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.

Topic Business strategies Drug development landscape

View article
Scrip

Second Spring? Coverage Expansion Fuels Big Pharma China Growth But '4+7' Impact Lingers

By Brian Yang 01 Nov 2019

AstraZeneca, Novartis and Roche deliver north of 20% sales growth in China again, driven by expanded reimbursement coverage and new product launches, but some clouds are on the horizon over falling sales due to the impact of the expanding “4+7” centralized procurement scheme.

Topic Company analysis

View article
Scrip

Interview: AstraZeneca 'Is More Than Oncology'

By Sten Stovall 01 Nov 2019

Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”

Topic Business strategies Drug development landscape

View article